Transaction Date | Company Name | Insider Name (Title) | Activity | Stock | Acquired or Disposed | Shares | Price range | Amount |
---|---|---|---|---|---|---|---|---|
2024-11-19 | NEKTAR THERAPEUTICS | Zalevsky Jonathan
(Chief R&D Officer) |
S | Common Stock | D | 7785 | $1.01 - $1.01 | $7,862 |
2024-11-19 | NEKTAR THERAPEUTICS | Wilson Mark Andrew
(Chief Legal Officer) |
S | Common Stock | D | 6407 | $1.01 - $1.01 | $6,471 |
2024-11-19 | NEKTAR THERAPEUTICS | ROBIN HOWARD W
(President & CEO) |
S | Common Stock | D | 16278 | $1.01 - $1.01 | $16,440 |
2024-08-19 | NEKTAR THERAPEUTICS | Zalevsky Jonathan
(Chief R&D Officer) |
S | Common Stock | D | 6866 | $1.28 - $1.28 | $8,788 |
2024-08-19 | NEKTAR THERAPEUTICS | Wilson Mark Andrew
(Chief Legal Officer) |
S | Common Stock | D | 5651 | $1.28 - $1.28 | $7,233 |
2024-08-19 | NEKTAR THERAPEUTICS | ROBIN HOWARD W
(President & CEO) |
S | Common Stock | D | 14881 | $1.28 - $1.28 | $19,047 |
2024-06-14 | NEKTAR THERAPEUTICS | CHESS ROBERT
(Director) |
S | Common Stock | D | 19500 | $1.20 - $1.20 | $23,400 |
A | Grant, award or other acquisition |
C | Conversion of Derivative or Security |
D | Disposition to the issuer of issuer equity securities |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability |
G | Bona fide Gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary Transaction |
J | Other acquisition or disposition |
K | Transaction in equity swap or instrument with similar characteristics |
L | Small Acquisition |
M | Exercise or conversion of derivative security |
O | Exercise of out-of-the-money derivative security |
P | Open Market Purchase |
S | Open Market Sale |
U | Disposition pursuant to a tender of shares in a change of control transaction |
V | Transaction Voluntarily Reported |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |